ATE188740T1 - Viruspartikel mit veraendertem wirtspektrum - Google Patents

Viruspartikel mit veraendertem wirtspektrum

Info

Publication number
ATE188740T1
ATE188740T1 AT91915104T AT91915104T ATE188740T1 AT E188740 T1 ATE188740 T1 AT E188740T1 AT 91915104 T AT91915104 T AT 91915104T AT 91915104 T AT91915104 T AT 91915104T AT E188740 T1 ATE188740 T1 AT E188740T1
Authority
AT
Austria
Prior art keywords
methods
altered host
incorporation
virus particles
disclosed
Prior art date
Application number
AT91915104T
Other languages
English (en)
Inventor
Jiing-Kuan Yee
Nobuhiko Emi
Theodore Friedman
Douglas J Jolly
Original Assignee
Univ California
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24642035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE188740(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Chiron Corp filed Critical Univ California
Application granted granted Critical
Publication of ATE188740T1 publication Critical patent/ATE188740T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91915104T 1991-02-19 1991-08-09 Viruspartikel mit veraendertem wirtspektrum ATE188740T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65863291A 1991-02-19 1991-02-19
PCT/US1991/005699 WO1992014829A1 (en) 1991-02-19 1991-08-09 Viral particles having altered host range

Publications (1)

Publication Number Publication Date
ATE188740T1 true ATE188740T1 (de) 2000-01-15

Family

ID=24642035

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915104T ATE188740T1 (de) 1991-02-19 1991-08-09 Viruspartikel mit veraendertem wirtspektrum

Country Status (6)

Country Link
EP (1) EP0572401B2 (de)
JP (1) JP3547129B2 (de)
AT (1) ATE188740T1 (de)
CA (1) CA2104396C (de)
DE (1) DE69131908T3 (de)
WO (1) WO1992014829A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
CA2133411A1 (en) * 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
AU689755B2 (en) * 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
EP0746625B1 (de) * 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Erzielbare vektorenpartikel
WO1995006717A2 (en) * 1993-09-03 1995-03-09 Viagene, Inc. Methods of suppressing graft rejection
WO1996009400A1 (en) * 1994-09-19 1996-03-28 Systemix, Inc. Methods for genetically modifying hematopoietic stem cells
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US6117681A (en) * 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
US5750396A (en) * 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines
JPH11507244A (ja) * 1995-10-05 1999-06-29 カイロン コーポレイション Ｓｒｖ−３エンベロープ糖タンパク質配列で偽型化したレトロウイルスベクター
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US5739018A (en) * 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
AU4340397A (en) 1996-09-11 1998-04-02 Biogen, Inc. Non-mammalian dna virus having an altered coat protein
US6183993B1 (en) 1996-09-11 2001-02-06 The General Hospital Corporation Complement-resistant non-mammalian DNA viruses and uses thereof
US6281009B1 (en) 1996-09-11 2001-08-28 The General Hospital Corporation Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell
US6818209B1 (en) 1998-05-22 2004-11-16 Oxford Biomedica (Uk) Limited Retroviral delivery system
WO1999061639A2 (en) * 1998-05-22 1999-12-02 Oxford Biomedica (Uk) Limited Retroviral delivery system
US6300488B1 (en) 1997-07-10 2001-10-09 The Salk Institute For Biological Studies Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
CA2334170A1 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US7504253B2 (en) 1999-06-11 2009-03-17 The Burnham Institute For Medical Research Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
US6864085B2 (en) 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
CN102151337B (zh) 2000-03-13 2014-03-12 恩根尼公司 调节消化道蛋白表达的组合物和方法
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
US7070993B2 (en) 2001-03-13 2006-07-04 Novartis Ag Lentiviral packaging constructs
CA2524619A1 (en) 2005-11-22 2007-05-22 Ottawa Health Research Institute Novel stem cells, nucleotide sequences and proteins therefrom
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2008152446A2 (en) 2006-11-27 2008-12-18 Patrys Limited Novel glycosylated peptide target in neoplastic cells
CA2677273A1 (en) 2007-02-06 2008-08-14 Tai-June Yoo Use of a composition comprising a cytokine encoding nucleic acid for treating alzheimer's disease
EP2185694A2 (de) 2007-08-02 2010-05-19 California Stem Cell, Inc. Neuronale vorläuferzellen und verfahren zur ableitung und reinigung neuronaler vorläuferzellen aus embryonischen stammzellen
US9593340B2 (en) 2007-10-15 2017-03-14 Admedus Vaccines Pty Ltd. Expression system for modulating an immune response
CA2704232C (en) 2007-11-08 2017-05-02 Dana-Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
EP2252317B1 (de) 2008-02-15 2014-04-09 Tufts University Behandlung von makuladegeneration
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
US8999919B2 (en) 2008-10-22 2015-04-07 Trustees Of Dartmouth College Compositions and methods for inhibiting the interaction between CFTR and CAL
US8211487B2 (en) 2008-11-26 2012-07-03 Srinivasan Damodaran Inhibition of ice crystal growth
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
JP5694923B2 (ja) 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
US9556272B2 (en) 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2012021891A2 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of complement-related disorders
CN103998057A (zh) 2011-09-15 2014-08-20 美国加州大学洛杉矶海滨分校医学中心的洛杉矶生物医学研究所 利用CotH的毛霉菌病的免疫疗法和诊断
WO2013162748A1 (en) 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
EP2953970A4 (de) 2013-02-08 2016-06-29 Misfolding Diagnostics Inc Transthyretinantikörper und verwendungen davon
EP3003393A4 (de) 2013-06-04 2017-01-11 The Johns Hopkins University Dreiteilige theranostische krebs-nukleinsäurekonstrukte
EP3004357A4 (de) 2013-06-04 2017-01-11 The Johns Hopkins University Peg-prom-vermittelte oberflächenexpression von avidin/streptavidin
WO2014209553A1 (en) 2013-06-04 2014-12-31 Virginia Commonwealth University Use of a truncated ccn1 promoter for cancer diagnostics, therapeutics and theranostics
EP3004872B1 (de) 2013-06-04 2017-10-18 Virginia Commonwealth University Mda-9/syntenin-promotor zur abbildung und behandlung metastatischer krebszellen
WO2014197535A1 (en) 2013-06-04 2014-12-11 Virginia Commonwealth University Recombinant cancer therapeutic cytokine
US20160152952A1 (en) 2013-06-25 2016-06-02 Temple University-Of The Commonwealth System Of Higher Education Cortical Bone-Derived Stem Cells
AU2015308773B2 (en) 2014-08-28 2021-03-25 Tufts University Compositions, methods and kits for treating complement related disorders
US9901639B2 (en) 2015-02-13 2018-02-27 Temple University—Of the Commonwealth System of Higher Education Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease
CN105372433A (zh) * 2015-08-21 2016-03-02 深圳出入境检验检疫局动植物检验检疫技术中心 一种水泡性口炎病毒抗体快速检测试纸条
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
CA3006779A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
WO2017180713A1 (en) 2016-04-13 2017-10-19 Orimabs Ltd. Anti-psma antibodies and use thereof
EP3299460A1 (de) 2016-09-26 2018-03-28 Johann Wolfgang Goethe-Universität Frankfurt am Main Neuartige verbindungen und verfahren zur modulation der ubiquitinierung
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
AU2018322482B2 (en) 2017-08-22 2024-04-04 Monash University Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (RAGE)
KR20200119311A (ko) 2018-02-12 2020-10-19 트러스티즈 오브 터프츠 칼리지 인플라마좀 활성화를 억제하기 위한 cd59
US12233135B2 (en) 2018-04-11 2025-02-25 Precision Molecular Inc. Therapeutic constructs for treating cancer
JP7765379B2 (ja) 2019-08-12 2025-11-06 ピュリノミア バイオテック， インコーポレイテッド Ｃｄ３９発現細胞のａｄｃｃ標的化を介してｔ細胞媒介性免疫応答を促進及び増強するための方法及び組成物
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
EP4412711A1 (de) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serumhalbwertszeiterweiterte pd-l1-bindende polypeptide
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
KR20240107156A (ko) 2021-11-19 2024-07-08 얀센 바이오테크 인코포레이티드 가용성 cd59를 발현하는 유전자 요법 벡터를 이용한 지도형 위축의 치료 방법
WO2023212483A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
IL327480A (en) 2023-10-02 2026-05-01 Janssen Biotech Inc Methods for treating macular degeneration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
FR2619012B1 (fr) * 1987-08-07 1989-12-22 Pasteur Institut Vaccins dont l'epitope caracteristique est incorpore dans une proteine de picornavirus, notamment de poliovirus
CA2002839C (en) * 1988-11-14 2000-10-10 Neal S. Young Parvovirus capsids
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
EP1288304A3 (de) * 1989-06-01 2006-04-05 Applied Biotechnology, Inc. Selbstzusammengesetzte, Defekte, sich Nichtselbstvermehrende
WO1991002508A1 (de) * 1989-08-21 1991-03-07 Brackmann Hans Peter Tragbare datenerfassungsvorrichtung therapierelevanter ereignisse
EP0897987B1 (de) * 1989-10-24 2001-02-28 Chiron Corporation Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein

Also Published As

Publication number Publication date
EP0572401A1 (de) 1993-12-08
AU663470B2 (en) 1995-10-12
EP0572401B2 (de) 2007-11-07
JPH06504905A (ja) 1994-06-09
EP0572401B1 (de) 2000-01-12
DE69131908T3 (de) 2008-04-03
AU8430291A (en) 1992-09-15
CA2104396A1 (en) 1992-08-20
WO1992014829A1 (en) 1992-09-03
DE69131908D1 (de) 2000-02-17
DE69131908T2 (de) 2000-08-17
JP3547129B2 (ja) 2004-07-28
CA2104396C (en) 2000-10-10

Similar Documents

Publication Publication Date Title
DE69131908D1 (de) Viruspartikel mit veraendertem wirtspektrum
NO871785D0 (no) Fremgangsmaate for fremstilling av et proteinprodukt, samt vektorsystem for fremgangsmaatens utfoerelse.
DE69638314D1 (de) Zirkuläres DNA Molekül mit einem abhängigen Replikationsursprung, seine Herstellungsverfahren und seine Verwendung in der Gentherapie
DK0561890T3 (da) DNA ekspressionssystemer baseret på alphavira
GB2199328B (en) Use of a 5' untranslated leader sequence of an rna virus to enhance translation
ATE114476T1 (de) Tierische zelle mit darin eingeführtem antigenem protein.
DE69434820D1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
AU1138388A (en) Hybrid rna virus
ATE43635T1 (de) Verfahren zur herstellung von interferon und expressionsvektoren dafuer.
ATE196507T1 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
CZ63995A3 (en) Virus vectors and their use in gene therapy
DE69333471D1 (de) Erzielbare vektorenpartikel
DE69921435D1 (de) Verfahren zur Inaktivierung vom umhüllten Viren in einem Viruspräparat mit Adenoviren
ATE352634T1 (de) Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
GR3024137T3 (en) A modified transcription control unit and uses thereof
DE3750348D1 (de) Verfahren zur Herstellung von Peptiden, dazu zu verwendendes rekombinantes Plasmid und mit diesem Plasmid transformierte Myelomzellen.
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
NO178870C (no) Fremgangsmåte for fremstilling av modifisert Eglin B eller C samt DNA, ekspresjonsvektor og vertsmikroorganisme
EP0836484A4 (de) In-vitro verpackung von adeno-assozierten virus dns
Will et al. Hepatitis B after infection of a chimpanzee with cloned HBV DNA
JPS5545618A (en) Thermal treatment of fraction containing glycoprotein which accelerates differentiation and proliferation of human granulocyte
ES2175184T3 (es) Virus que expresan proteinas toxicas y leneas celulares productoras.
Bosworth et al. Evaluation of age-related effects on the antiviral activity of interferon and induction of 2-5A synthetase in testicular cell cultures derived from swine of various ages
EP0460217A4 (en) Cdna of orsv gene
ATE52798T1 (de) Hepatitis-b-virus-gen enthaltendes rekombinantes plasmid, mit diesem rekombinanten plasmid transformierte hefe und herstellung von hepatitis-b-virus-oberflaechenantigen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties